Episode

Episode 510: ADCs in Prostate Cancer

Podcast: The Uromigos
Published: Jun 15, 2026
Duration seconds: 1823
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-510-ADCs-in-Prostate-Cancer-e3kqflf
Audio: https://anchor.fm/s/13347ea8/podcast/play/121502831/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-15%2F426173003-44100-2-d76fc9cd3be71.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-510-adcs-in-prostate-cancer
Markdown: /podcast/the-uromigos-1214845/episode-510-adcs-in-prostate-cancer.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-510-adcs-in-prostate-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-510-adcs-in-prostate-cancer.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.